Ardelyx (ARDX) to Release Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX - Get Free Report) is expected to be announcing its Q4 2024 earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $111.16 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.02. Ardelyx had a negative return on equity of 46.60% and a negative net margin of 28.82%. The company had revenue of $116.13 million for the quarter, compared to the consensus estimate of $111.16 million. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Stock Down 8.7 %

ARDX stock traded down $0.50 during trading on Friday, reaching $5.23. 3,880,423 shares of the stock were exchanged, compared to its average volume of 4,344,817. The firm's 50 day moving average is $5.30 and its 200 day moving average is $5.64. Ardelyx has a twelve month low of $4.32 and a twelve month high of $9.83. The company has a current ratio of 4.03, a quick ratio of 3.87 and a debt-to-equity ratio of 0.64. The firm has a market cap of $1.24 billion, a P/E ratio of -17.38 and a beta of 0.85.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Jefferies Financial Group dropped their price target on Ardelyx from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, January 2nd. Piper Sandler upped their price target on Ardelyx from $7.00 to $8.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Citigroup dropped their price target on Ardelyx from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Cantor Fitzgerald raised Ardelyx to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, Raymond James reaffirmed a "strong-buy" rating and set a $13.00 price target (down from $15.00) on shares of Ardelyx in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $9.93.

Insider Transactions at Ardelyx

In other news, CEO Michael Raab sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $5.26, for a total value of $131,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,150,385 shares of the company's stock, valued at $6,051,025.10. This represents a 2.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David M. Mott bought 213,300 shares of Ardelyx stock in a transaction dated Thursday, December 19th. The stock was acquired at an average cost of $4.67 per share, with a total value of $996,111.00. Following the completion of the acquisition, the director now owns 1,638,765 shares of the company's stock, valued at $7,653,032.55. This represents a 14.96 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 133,332 shares of company stock valued at $710,576 over the last ninety days. 5.90% of the stock is currently owned by insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.